MA47511A - Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants - Google Patents

Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants

Info

Publication number
MA47511A
MA47511A MA047511A MA47511A MA47511A MA 47511 A MA47511 A MA 47511A MA 047511 A MA047511 A MA 047511A MA 47511 A MA47511 A MA 47511A MA 47511 A MA47511 A MA 47511A
Authority
MA
Morocco
Prior art keywords
intermediaries
processes
preparation
corresponding salts
salts
Prior art date
Application number
MA047511A
Other languages
English (en)
Inventor
Mamoun Alhamadsheh
Pooran Chand
Yogesh Kumar Gupta
Rakesh Kumar Kumawat
Robert Zamboni
Original Assignee
Eidos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidos Therapeutics Inc filed Critical Eidos Therapeutics Inc
Publication of MA47511A publication Critical patent/MA47511A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA047511A 2017-02-17 2018-02-16 Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants MA47511A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762460576P 2017-02-17 2017-02-17

Publications (1)

Publication Number Publication Date
MA47511A true MA47511A (fr) 2019-12-25

Family

ID=63166944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047511A MA47511A (fr) 2017-02-17 2018-02-16 Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants

Country Status (17)

Country Link
US (4) US10513497B2 (fr)
EP (1) EP3582773A4 (fr)
JP (2) JP7157752B2 (fr)
KR (2) KR20240068787A (fr)
CN (3) CN110381940B (fr)
AU (2) AU2018222739C1 (fr)
BR (1) BR112019016935A2 (fr)
CA (1) CA3051357A1 (fr)
CL (1) CL2019002321A1 (fr)
EA (1) EA201991921A1 (fr)
IL (2) IL298196A (fr)
MA (1) MA47511A (fr)
MX (3) MX2021015220A (fr)
NZ (1) NZ755597A (fr)
SG (1) SG11201906922TA (fr)
TW (2) TWI791487B (fr)
WO (1) WO2018151815A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
JP2021518381A (ja) 2018-03-23 2021-08-02 エイドス セラピューティクス，インコーポレイティド Ａｇ１０を使用するｔｔｒアミロイドーシスの治療方法
US11260047B2 (en) 2018-08-17 2022-03-01 Eidos Therapeutics, Inc. Formulations of AG10
US20220071965A1 (en) 2018-12-20 2022-03-10 Pfizer Inc. Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent
WO2022112919A1 (fr) 2020-11-25 2022-06-02 Pfizer Inc. Composés de pyrazole substitués par (aza)benzothiazolyle
WO2023009612A1 (fr) 2021-07-28 2023-02-02 Protego Biopharma, Inc. Dérivés d'acoramidis (acide 3-(3-(3,5-diméthyl-1h-pyrazol-4-yl)propoxy)-4-fluorobenzoïque) pour stabiliser la transthyrétine (tts) et inhiber un mauvais repliement de la tts pour le traitement, par ex., de l'amyloïdose à ttr périphérique
WO2023052652A1 (fr) 2021-10-01 2023-04-06 Sandoz Ag Forme cristalline d'acoramidis chlorhydrate

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
HU224548B1 (hu) 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
EP0968711B9 (fr) 1997-10-28 2008-05-28 Bando Chemical Industries, Ltd. Feuille de timbre cutane et procede de production d'une feuille de base pour timbre
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
EP1248869A2 (fr) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害；癌、および他の疾患を治療するｎ−置換複素環
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
WO2004096808A1 (fr) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Composes de triazine et leur utilisation
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006009826A1 (fr) 2004-06-18 2006-01-26 3M Innovative Properties Company Thiazoloquinolines et thiazolonaphtyridines substitues par aryloxy et arylalkyleneoxy
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (fr) 2005-02-14 2006-08-24 Wyeth THIÉNYL- ET FURYLACYLGUANIDINE SUBSTITUÉES ET MÉTHODES D'EMPLOI DESDITS COMPOSÉS EN TANT QUE RÉGULATEURS DE LA β-SECRÉTASE
EP1919288A4 (fr) 2005-07-18 2009-12-16 Horizon Therapeutics Inc Medicaments contenant famotidine et ibuprofene, et administration desdits medicaments
KR101450356B1 (ko) * 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 ｎ-(메틸)-1ｈ-피라졸-3-아민, ｎ-(메틸)-피리딘-2-아민 및 ｎ-(메틸)-티아졸-2-아민 유도체
WO2008077597A1 (fr) 2006-12-22 2008-07-03 Novartis Ag Dérives de 1-aminométhyl- l- phényl- cyclohexane comme inhibiteurs de ddp-iv
PL2155717T3 (pl) 2007-05-11 2013-03-29 Lilly Co Eli 2-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-3-FENYLO PIRAZYNY I PIRYDYNY I 3-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-2-FENYLO PIRYDYNY JAKO ANTAGONIŚĆI RECEPTORA 5-HT<sub>7</sub>
TWI443090B (zh) 2007-05-25 2014-07-01 Abbvie Deutschland 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物
DE602008002205D1 (de) 2007-06-06 2010-09-30 Torrent Pharmaceuticals Ltd Neuartige verbindungen
AU2008262038A1 (en) 2007-06-08 2008-12-18 AbbVie Deutschland GmbH & Co. KG 5-heteroaryl substituted indazoles as kinase inhibitors
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
EA019033B1 (ru) 2008-03-26 2013-12-30 Новартис Аг Ингибиторы дезацетилазы в, основанные на гидроксамате
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
SI2344639T1 (sl) 2008-10-20 2015-09-30 Alnylam Pharmaceuticals, Inc. Sestavki in postopki inhibicije izražanja transtiretina
JP5743897B2 (ja) 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
EP2566333A4 (fr) 2010-05-07 2014-04-02 Univ Leland Stanford Junior Identification de stabilisants de protéines multimériques
EP2651957B1 (fr) 2010-12-16 2015-02-18 Allergan, Inc. Dérivés phosphoreux en tant que modulateurs de récepteur de chimiokine
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
JP6543342B2 (ja) * 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
EP3607939B1 (fr) 2015-06-30 2022-06-01 Gilead Sciences, Inc. Formulations pharmaceutiques comprenant tenofovir et emtricitabine
AU2016304408B2 (en) 2015-07-31 2019-02-21 Pfizer Inc., 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
JP2021518381A (ja) 2018-03-23 2021-08-02 エイドス セラピューティクス，インコーポレイティド Ａｇ１０を使用するｔｔｒアミロイドーシスの治療方法
US11260047B2 (en) 2018-08-17 2022-03-01 Eidos Therapeutics, Inc. Formulations of AG10

Also Published As

Publication number Publication date
MX2019009764A (es) 2019-11-11
JP2020507618A (ja) 2020-03-12
US20220041558A1 (en) 2022-02-10
CN116730921A (zh) 2023-09-12
US20240239751A1 (en) 2024-07-18
AU2024204057A1 (en) 2024-07-04
WO2018151815A1 (fr) 2018-08-23
TWI791487B (zh) 2023-02-11
TWI849678B (zh) 2024-07-21
NZ755597A (en) 2023-06-30
CL2019002321A1 (es) 2019-12-27
KR20240068787A (ko) 2024-05-17
EA201991921A1 (ru) 2020-02-06
CN110381940A (zh) 2019-10-25
MX2022015151A (es) 2023-02-01
US20180237396A1 (en) 2018-08-23
US10513497B2 (en) 2019-12-24
MX2021015220A (es) 2022-12-01
AU2018222739C1 (en) 2024-10-03
JP7157752B2 (ja) 2022-10-20
TW201835053A (zh) 2018-10-01
KR102665258B1 (ko) 2024-05-10
AU2018222739A1 (en) 2019-08-22
IL268683A (en) 2019-10-31
EP3582773A1 (fr) 2019-12-25
AU2018222739B2 (en) 2024-03-14
US11919865B2 (en) 2024-03-05
TW202342430A (zh) 2023-11-01
BR112019016935A2 (pt) 2020-04-07
JP2022183220A (ja) 2022-12-08
US20200247756A1 (en) 2020-08-06
CN116730920A (zh) 2023-09-12
CN110381940B (zh) 2023-07-21
IL298196A (en) 2023-01-01
IL268683B2 (en) 2023-04-01
EP3582773A4 (fr) 2021-03-10
KR20190130128A (ko) 2019-11-21
IL268683B (en) 2022-12-01
SG11201906922TA (en) 2019-09-27
CA3051357A1 (fr) 2018-08-23
US11078162B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
MA47511A (fr) Procédés de préparation d&#39;ag-10, de ses intermédiaires et de sels correspondants
WO2015153889A3 (fr) Substances et procédés pour le traitement d&#39;une infection virale latente
MA48779A (fr) Formes cristallines d&#39;inhibiteur de fgfr et leurs procédés de préparation
WO2016149710A3 (fr) Anticorps neutralisant le vih-1 et leurs utilisations
WO2015001504A3 (fr) Formulations d&#39;anticorps et procédés correspondants
EP3505620A4 (fr) Organoïde 2d pour l&#39;infection et la culture de virus de la diarrhée humaine, et utilisation dudit organoïde 2d
MA45154A (fr) Procédés de préparation d&#39;oligomères
MA52906A (fr) Procédé de préparation d&#39;amg 416
MA45155A (fr) Procédés de préparation d&#39;oligomères morpholino de phosphorodiamidate
MA51629A (fr) Procédés de production, purification et formulation de conjugués anticorps-médicaments
WO2016069142A3 (fr) Dispositifs de mesure de la fonction contractile, systèmes associés et procédés d&#39;utilisation correspondants
BR112019004911A2 (pt) oligonucleotídeos modificados e métodos de uso
MA45183A (fr) Procédés de préparation d&#39;oligomères morpholino de phosphorodiamidate
EP3313818A4 (fr) Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l&#39;aide de composés immunomodulateurs et utilisations de biomarqueurs
IL260665B (en) Improved process for the preparation of osimertinib (azd9291) or its salt and &#34;azd9291 aniline&#34; or its salt
EP3405183A4 (fr) Dérivés d&#39;adamatane pour le traitement d&#39;une infection à filovirus
EP3450483A4 (fr) Nouvel organopolysiloxane ou sel de neutralisation d&#39;acide de celui-ci, et utilisations de ceux-ci
MA50124A (fr) Procédé de préparation de tubulysines et d&#39;intermédiaires de celles-ci
FR3048968B1 (fr) Procede de preparation d&#39;alkylamines
MA51432A (fr) Procédé de préparation d&#39;une amino-pyrimidine et de ses intermédiaires
IL274843A (en) A system for biological water treatment
FR3049599B1 (fr) Procede de preparation de l&#39;hexafluorobutadiene.
MA49555A (fr) Procédé amélioré de préparation d&#39;imetelstat
MA51510A (fr) Procédés de préparation de dérivés d&#39;indolinobenzodiazépine
EP3589272A4 (fr) Procédés pour prévenir par prophylaxie, ralentir l&#39;évolution ou traiter la maladie d&#39;alzheimer